honokiol has been researched along with Multiple Myeloma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arbiser, JL; Bonner, MY; Cebula-Obrzut, B; Majchrzak, A; Mędra, A; Robak, T; Smolewski, P; Witkowska, M | 1 |
Anderson, KC; Arbiser, J; Chauhan, D; Hamasaki, M; Hideshima, H; Hideshima, T; Ishitsuka, K; Kumar, S; Le Gouill, S; Podar, K; Raje, N; Richardson, P; Roccaro, AM; Shiraishi, N; Tamura, K; Yasui, H | 1 |
2 other study(ies) available for honokiol and Multiple Myeloma
Article | Year |
---|---|
Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Leukemia; Lignans; Lymphoma; Multiple Myeloma; Trityl Compounds | 2016 |
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biphenyl Compounds; Bone Marrow Cells; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Endothelial Cells; Humans; Insulin-Like Growth Factor I; Interleukin-6; Lignans; Multiple Myeloma; Neovascularization, Pathologic; Stromal Cells; Structure-Activity Relationship | 2005 |